Glutathione Peroxidases 1 and 3 Immunoscores in Clear Cell Renal Cell Carcinoma: New Insights from a Case-Series Study
Oncology Research · 2026
DOI: 10.32604/or.2026.077195 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2026. Verfasst von Dimitra P Vageli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Glutathione Peroxidase, Kidney Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, with a poor prognosis in advanced stages. Although histological tumor grading is an established prognostic parameter, it often fails to capture the biological heterogeneity of RCC. Therefore, identifying novel biomarkers could enhance early diagnosis and improve predictive accuracy. Here, we aimed to test whether immunophenotypes of specific glutathione peroxidase (GPX) family members may have prognostic value in RCC.
Methods
We investigated the relationship between GPX1 and GPX3 immunophenotypes and clinicopathological parameters in 32 surgical specimens of clear cell RCC (ccRCC) with nucleolar grade 1-4 (WHO/ISUP grading). We evaluated the GPX1 and GPX3 immunophenotypes and assigned a histological immunoscore for each marker. For analysis, we used Spearman and point-biserial correlation methods.
Results
Our findings indicated a significant positive correlation between GPX1 immunoscore and high nucleolar grade (r = 0.80, p 0.05), nor with capsular infiltration and invasion of the renal pelvis (p > 0.05). However, we did find statistically significant positive correlations between GPX1 expression and invasion of the renal vein (p = 0.038), perirenal fat (p = 0.043), and peripyelic fat (p = 0.015).
Conclusion
Our data demonstrate that GPX1 and GPX3 immunophenotypes could have a prognostic role for ccRCC, particularly in relation to nucleolar grade. This study has limitations because of the small sample size; however, it underscores the necessity for further research in larger, prospective studies. These studies should more thoroughly examine the associations between GPX1 and GPX3 and clinicopathological parameters, and validate them as potential novel prognostic biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
- Center of Neuroscience and Regeneration Research Center, Yale University School of Medicine & VA-Connecticut Healthcare System, West Haven, CT, USA.
- Department of Neurology, Yale School of Medicine, New Haven, CT, USA.
- Cancer Signaling Networks Program, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
- Department of Medicine, Rutgers-Robert Wood Johnson Medical School/Saint Peter's University Hospital, New Brunswick, NJ, USA.
- Pathology Anatomy Laboratory, University General Hospital of Larissa, Mezourlo Larissa, Larissa, Greece.
Zitieren
APA
Vageli, D. P., Doukas, P. G., Papageorgiou, N., Markou, C. A., Zacharouli, K., & Ioannou, M. (2026). Glutathione Peroxidases 1 and 3 Immunoscores in Clear Cell Renal Cell Carcinoma: New Insights from a Case-Series Study. Oncology Research. https://doi.org/10.32604/or.2026.077195
Vancouver
Vageli DP, Doukas PG, Papageorgiou N, Markou CA, Zacharouli K, Ioannou M. Glutathione Peroxidases 1 and 3 Immunoscores in Clear Cell Renal Cell Carcinoma: New Insights from a Case-Series Study. Oncology Research. 2026. doi:10.32604/or.2026.077195
BibTeX
@article{Vageli2026,
author = {Vageli, Dimitra P and Doukas, Panagiotis G and Papageorgiou, Nikolaos and Markou, Chrysanthi A and Zacharouli, Konstantina and Ioannou, Maria},
title = {Glutathione Peroxidases 1 and 3 Immunoscores in Clear Cell Renal Cell Carcinoma: New Insights from a Case-Series Study},
journal = {Oncology Research},
year = {2026},
doi = {10.32604/or.2026.077195}
}
EUVIMED